Skip to main content
SpringerLink
Log in

Kyleena™ (levonorgestrel-releasing intrauterine system) in contraception: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Kyleena™ is a levonorgestrel (LNG) intrauterine system (IUS) that releases 12 μg of LNG daily during the first year of use (LNG-IUS 12). It is the first low-dose LNG IUS approved for use for up to 5 years. Clinical trials in nulliparous and parous women demonstrated that LNG-IUS 12 is highly effective in preventing pregnancy and generally well tolerated for periods of up to 5 years. Kyleena™ has a smaller hormone reservoir and T-frame than some other LNG IUSs, including Mirena®, and, thus, has a smaller placement tube. Bleeding experienced by women using LNG-IUS 12 in clinical trials became less frequent over time, as did the overall incidence of treatment-related adverse events. LNG-IUS 12 was associated with high levels of user satisfaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stoddard A, McNicholas C, Peipert JF. Efficacy and safety of long-acting reversible contraception. Drugs. 2011;71(8):969–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hsia JK, Creinin MD. Intrauterine contraception. Semin Reprod Med. 2016;34(3):175–82.

    Article  PubMed  Google Scholar 

  3. Mirena 20 µg/24 hours intrauterine delivery system: summary of product characteristics. Newbury, Berkshire, UK: Bayer plc; 2015.

  4. Kyleena 19.5 mg intrauterine delivery system: EU summary of product characteristics. London: European Medicines Agency; 2016.

  5. Kyleena (levonorgestrel-releasing intrauterine system): US prescribing information. Whippany (NJ):Bayer HealthCare Pharmaceuticals Inc.; 2016.

  6. Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013;122(6):1205–13.

    Article  CAS  PubMed  Google Scholar 

  7. Skyla (levonorgetrel-releasing intrauterine system): US prescribing information. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc.; 2016.

  8. Apter D, Gemzell-Danielsson K, Hauck B, et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014;101(6):1656–62.e1-4.

  9. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97(3):616–22.e1-3.

  10. Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low dose levonorgestrel intrauterine contraceptive system over 5 years of use. Eur J Obstet Gynecol Reprod Biol. 2016;210:22–8.

    Article  PubMed  Google Scholar 

  11. Gemzell-Danielsson K, Apter D, Hauck B, et al. The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: subgroup analyses of data from a phase III trial. PLoS One. 2015;10(9):e0135309.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Nahum GG, Kaunitz AM, Rosen K, et al. Ovarian cysts: presence and persistence with use of a 13.5 mg levonorgestrel-releasing intrauterine system. Contraception. 2015;91(5):412–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This article was reviewed by: D. Apter, VL-Medi Clinical Research Center, Helsinki, Finland; L. Bahamondes, Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil; K.J. Bühling, Department of Gynecological Endocrinology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; S.M. Dermout, Gynaecologisch Centrum Dermout & Albicher, Alkmaar, the Netherlands; O. Heikinheimo, Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. During the peer review process, the manufacturer of Kyleena™ was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Kate McKeage & Katherine A. Lyseng-Williamson

Authors
  1. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

K McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McKeage, K., Lyseng-Williamson, K.A. Kyleena™ (levonorgestrel-releasing intrauterine system) in contraception: a profile of its use. Drugs Ther Perspect 33, 202–207 (2017). https://doi.org/10.1007/s40267-017-0395-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-017-0395-9

Keywords

Search

Navigation